|
Malignant neoplasm of stomach
|
0.320 |
Biomarker
|
disease |
BEFREE |
Kaplan-Meier analysis revealed that low tumor expression of PDHA1 was significantly correlated with a poorer overall survival in patients with GC (5-year overall survival rates for patients with low vs high PDHA1 expression = 49.8% vs 72.7%, hazard ratio of death from GC = 2.594, 95% CI = 1.527 to 4.408, P < 0.001).
|
30611622 |
2019 |
|
Cerebral Palsy
|
0.110 |
Biomarker
|
disease |
BEFREE |
In 23 patients molecular diagnosis was reached and included 5 hereditary spastic paraplegia genes (SPG) in spastic CP mimics; HPRT1, TH, QDPR, DDC in dystonic CP mimics; ADCY5 and NIKX2-1 in choreic CP mimics; CANA1A in ataxic CP mimics; and SPG, PDHA1, NIKX2-1, AT, SLC2A1 and SPR in mixed CP mimics.
|
30799092 |
2019 |
|
Ataxia
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
A total of 5 pedigrees were finally genetically diagnosed as mitochondrial ataxia, with 3 pathogenic mutations (m.8344A>G, m.9176T>C, and m.9185T>C), one likely pathogenic mutation (m.3995A>G) in mtDNA, and one pathogenic mutation (c.1159_1162dupAAGT, p.Ser388Terfs) in PDHA1.
|
29756269 |
2019 |
|
Cerebellar Ataxia
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
A total of 5 pedigrees were finally genetically diagnosed as mitochondrial ataxia, with 3 pathogenic mutations (m.8344A>G, m.9176T>C, and m.9185T>C), one likely pathogenic mutation (m.3995A>G) in mtDNA, and one pathogenic mutation (c.1159_1162dupAAGT, p.Ser388Terfs) in PDHA1.
|
29756269 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Pyruvate dehydrogenase E1α subunit (PDHA1) is one of the main factors for the metabolic switch from oxidative phosphorylation (OXPHOS) to aerobic glycolysis and has been suggested to be closely associated with tumorigenesis.
|
29444744 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
SIRT3 elicited an anti-Warburg effect through HIF1α/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis.
|
30993888 |
2019 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Kaplan-Meier analysis revealed that low tumor expression of PDHA1 was significantly correlated with a poorer overall survival in patients with GC (5-year overall survival rates for patients with low vs high PDHA1 expression = 49.8% vs 72.7%, hazard ratio of death from GC = 2.594, 95% CI = 1.527 to 4.408, P < 0.001).
|
30611622 |
2019 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In contrast, insulin induced an increase of p-Ser264 PDHA1 levels in hepatocellular carcinoma HepG2 and Huh7 cells.
|
30226812 |
2019 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Collectively, our data indicate that reduced PDHA1 protein expression is associated with the poor clinical outcome of HCC.
|
29444744 |
2019 |
|
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, a KYSE450 PDHA1 knockout (KO) cell line of esophageal cancer was established by CRISPR/Cas9 technology.
|
31819487 |
2019 |
|
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, a KYSE450 PDHA1 knockout (KO) cell line of esophageal cancer was established by CRISPR/Cas9 technology.
|
31819487 |
2019 |
|
Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SIRT3 elicited an anti-Warburg effect through HIF1α/PDK1/PDHA1 to inhibit cholangiocarcinoma tumorigenesis.
|
30993888 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our previous studies have shown that low level of PDHA1 protein expression in esophageal squamous cell cancer (ESCC) was correlated with poor prognosis.
|
31819487 |
2019 |
|
Malignant neoplasm of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, a KYSE450 PDHA1 knockout (KO) cell line of esophageal cancer was established by CRISPR/Cas9 technology.
|
31819487 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Intriguingly, PDHA1 expression was significantly correlated with depth of invasion (P < 0.001), lymph node metastasis (P < 0.001), TNM stage (P < 0.001), and nerve invasion (P = 0.006).
|
30611622 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, LDHA/PDHA1 changes in HNSCC cells resulted in a broad metabolic reprogramming while intracellular molecules including polyunsaturated fatty acids and nitrogen metabolism related metabolites underlie the malignant changes.
|
31100640 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Intriguingly, PDHA1 expression was significantly correlated with depth of invasion (P < 0.001), lymph node metastasis (P < 0.001), TNM stage (P < 0.001), and nerve invasion (P = 0.006).
|
30611622 |
2019 |
|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
CTD_human |
Here, we found that genetic and pharmacological inactivation of pyruvate dehydrogenase A1 (PDHA1), a subunit of the pyruvate dehydrogenase complex (PDC), inhibits prostate cancer development in mouse and human xenograft tumor models by affecting lipid biosynthesis.
|
29335542 |
2018 |
|
Malignant neoplasm of prostate
|
0.330 |
Biomarker
|
disease |
BEFREE |
Here, we found that genetic and pharmacological inactivation of pyruvate dehydrogenase A1 (PDHA1), a subunit of the pyruvate dehydrogenase complex (PDC), inhibits prostate cancer development in mouse and human xenograft tumor models by affecting lipid biosynthesis.
|
29335542 |
2018 |
|
Malignant neoplasm of stomach
|
0.320 |
Biomarker
|
disease |
BEFREE |
Our results indicated that miR‑21‑5p targeted PDHA1 to regulate a metabolic switch and cancer progression in gastric cancer, and reveal the potential role of the miR‑21‑5p/PDHA1 axis in gastric cancer treatment.
|
30226598 |
2018 |
|
Prostatic Neoplasms
|
0.310 |
AlteredExpression
|
group |
BEFREE |
Additionally, we found that PDHA1 and the PDC activator pyruvate dehydrogenase phosphatase 1 (PDP1) are frequently amplified and overexpressed at both the gene and protein levels in prostate tumors.
|
29335542 |
2018 |
|
Prostatic Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Additionally, we found that PDHA1 and the PDC activator pyruvate dehydrogenase phosphatase 1 (PDP1) are frequently amplified and overexpressed at both the gene and protein levels in prostate tumors.
|
29335542 |
2018 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, we found that genetic and pharmacological inactivation of pyruvate dehydrogenase A1 (PDHA1), a subunit of the pyruvate dehydrogenase complex (PDC), inhibits prostate cancer development in mouse and human xenograft tumor models by affecting lipid biosynthesis.
|
29335542 |
2018 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
PDHA1 downregulation has been revealed in several types of cancer to enhance glycolysis.
|
30226598 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Here, we found that genetic and pharmacological inactivation of pyruvate dehydrogenase A1 (PDHA1), a subunit of the pyruvate dehydrogenase complex (PDC), inhibits prostate cancer development in mouse and human xenograft tumor models by affecting lipid biosynthesis.
|
29335542 |
2018 |